Sugi Predict

Sugi Predict / Compounds / SCHEMBL16770337

SCHEMBL16770337

SCHEMBL16770337

CCC(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=O)C(=O)Nc1ccc(COC(C)=O)cc1)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 11/20 0.44
▸ SIRT1 Q96EB6 10/20 0.44
▸ SIRT3 Q9NTG7 3/20 0.44
▸ HTT P42858 1/20 0.44
▸ FURIN P09958 2/20 0.43
▸ SIRT5 Q9NXA8 2/20 0.41
▸ NPY1R P25929 2/20 0.39
▸ NPY2R P49146 2/20 0.39
▸ NPY4R P50391 2/20 0.39
▸ NPY5R Q15761 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19485763 1.00 SIRT2 (0.44) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL84114 1.00 SIRT2 (0.44) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL24279693 0.93 SIRT1 (0.47) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL22420226 0.93 SIRT1 (0.47) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL19485818 0.93 SIRT2 (0.44) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL19485753 0.93 SIRT2 (0.44) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL17236057 0.93 SIRT2 (0.42) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL22536335 0.93 SIRT2 (0.46) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL16143151 0.93 SIRT2 (0.42) SIRT2SIRT1SIRT3HTTFURIN
SCHEMBL14887424 0.93 SIRT2 (0.42) SIRT2SIRT1SIRT3HTTFURIN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023124537-A1 CONJUGATE AND ANTIBODY-DRUG CONJUGATE PREPARED USING SAME 辽宁键凯科技有限公司 2023-07-06 — — WO disclosed
WO-2023097604-A1 ISOLATED POLYPEPTIDE AND USE THEREOF 岩唐生物科技(杭州)有限责任公司 2023-06-08 — — WO disclosed
EP-3925627-A1 DRUG-CONJUGATES AND USES THEREOF Concortis Biosystems, Corp (US) 2021-12-22 — — EP disclosed
US-9796754-B2 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives AMBRX, INC. (US) 2017-10-24 — — US disclosed
US-20170290925-A1 Conjugates And Conjugating Reagents POLYTHERICS LIMITED (GB) 2017-10-12 — — US disclosed
US-20170035903-A1 ANTIBODIES, ANTIBODY DRUG CONJUGATES AND METHODS OF USE EXELIXIS, INC. 2017-02-09 — — US disclosed
US-20150152190-A1 Prostate-Specific Membrane Antigen Antibody Drug Conjugates AMBRX, INC. (US) 2015-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170035903-A1 ANTIBODIES, ANTIBODY DRUG CONJUGATES AND METHODS OF USE GNRHR, FSHR, INHA SIRT2 1266/4885SIRT1 2269/4885SIRT3 1656/4885
US-20170290925-A1 Conjugates And Conjugating Reagents ANPEP, NGLY1, PCTP SIRT2 3785/4885SIRT1 3680/4885SIRT3 3296/4885
US-20150152190-A1 Prostate-Specific Membrane Antigen Antibody Drug Conjugates KLK3, PTMS, DDOST SIRT2 3189/4885SIRT1 3000/4885SIRT3 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.